Variables associated with 5-year persistence of TNFi
| Univariable analysis OR (95% CI)* | P value | Multivariable analysis OR (95% CI)* | P value | |
| Females | 0.5 (0.4to 0.7) | 0.0001 | 0.56 (0.40 to 0.78) | <0.001 |
| Age (years) | 1.0 (1.0 to 1.0) | 0.7 | 1.01 (1.00 to 1.03) | 0.08 |
| Disease duration (years) | 1.0 (1.0 to 1.0) | 0.2 | – | – |
| Previously used csDMARDs | 0.9 (0.8 to 1.0) | 0.2 | – | – |
| TNFi | ||||
| Infliximab | Ref | Ref | ||
| Etanercept | 2.1 (1.5 to 3.1) | 0.001 | 2.2 (1.5 to 3.2) | <0.001 |
| Adalimumab | 1.8 (1.1 to 3.0) | 0.02 | 1.8 (1.1 to 3.1) | 0.02 |
| Current smoker | 0.7 (0.4 to 1.0) | 0.05 | – | – |
| Comorbidity† | 0.6 (0.4 to 0.8) | 0.001 | 0.6 (0.4 to 0.8) | 0.001 |
| Depression | 0.8 (0.5 to 1.2) | 0.2 | – | – |
| Comedication | ||||
| None | Ref | – | – | |
| MTX‡ | 0.9 (0.6 to 1.3) | 0.6 | – | – |
| Other | 0.6 (0.3 to 1.0) | 0.05 | – | – |
| Baseline steroid use | 0.9 (0.6 to 1.4) | 0.7 | – | – |
| Patient global (0–100) | 1.00 (1.0 to 1.0) | 0.9 | – | – |
| DAS28 | 1.0 (0.9 to 1.2) | 0.9 | – | – |
| 28 tender joint count | 1.0 (1.0 to 1.0) | 0.1 | – | – |
| 28 swollen joint count | 1.0 (1.0 to 1.0) | 0.5 | – | – |
| ESR (mm/hour) | 1.0 (1.0 to 1.0) | 0.6 | – | – |
| CRP (mg/L) | 1.0 (1.0 to 1.0) | 0.4 | – | – |
| HAQ (0–3) | 0.7 (0.5 to 0.9) | 0.002 | – | – |
| SF-36 PCS | 1.0 (1.0 to 1.0) | 0.05 | – | – |
| SF-36 MCS | 1.0 (1.0 to 1.0) | 0.6 | – | – |
*Per unit increase (in continuous variables).
†≥1 of (previous or current) hypertension, angina, myocardial infarction, stroke, epilepsy, asthma, chronic obstructive airway disease, peptic ulcer disease, liver disease, renal disease, tuberculosis, demyelinating disease, diabetes, cancer.
‡Alone or in combination with other csDMARD.
CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MCS, Mental Component Score; MTX,methotrexate; PCS, Physical Component Score; SF-36, medical outcomes Study 36-item Short Form Health Survey; TNFi, tumour necrosis factor alpha inhibitor.